|
|
|
1-10 employees
View all
|
|
Biotechnology
|
|
San Carlos CA United States
|
|
Lion Biotechnologies is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (TILs). This approach, also known as adoptive T-cell therapy, was developed by Dr. Steven A. Rosenberg at the National Cancer Institute and is currently in use at leading cancer centers in the US. Our lead product candidate is an autologous, ready-to-infuse cell therapy that has demonstrated distinctive efficacy in the treatment of metastatic melanoma. In Phase 2 clinical trials conducted at NCI, patients treated with this product demonstrated objective response rates of 56%. In addition to metastatic melanoma, our TIL technology is potentially applicable to all solid tumors, including ovarian, colorectal, head and neck, and other cancers. As we continue advancing our current clinical programs, we are also developing next-generation TILs and an optimized manufacturing process that will enable the production of highly potent, engineered cells at a significantly reduced cost.
|
Lion Biotechnologies, Inc. Email Formats | Example Email Formats | Percentage |
---|---|---|
{first}.{last} | [email protected] |
100%
|
The widely used Lion Biotechnologies, Inc. email format is {first}.{last} (e.g. [email protected]) with 100% adoption across the company.
To contact Lion Biotechnologies, Inc. customer service number in your country click here to find.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.